GB2043641A - Cephalosporins - Google Patents

Description

1

GB 2 043 641 A

1

SPECIFICATION Cephalosporin antibiotics

5 This invention is concerned with cephalosporin compounds possessing valuable antibiotic properties.

The cephalosporin compounds in this specification are named with reference to "cepham" after J. Amer. Chem. Soc., 1962,84,3400, the term "cephem" referring to the basic cepham structure with one double bond.

Cephalosporin antibiotics are widely used in the treatment of diseases caused by pathogenic bacteria in 10 human beings and animals, and are especially useful in the treatment of diseases caused by bacteria which are resistant to other antibiotics such as penicillin compounds, and in the treatment of penicillin-sensitive patients. In many instances it is desirable to employ a cephalosporin antibiotic which exhibits activity against both gram-positive and gram-negative micro-organisms, and a significant amount of research has been directed to the development of various types of broad spectrum cephalosporin antibiotics.

15 Thus, for example, in our British Patent Specification No. 1,399,086, we describe a novel class of cephalosporin antibiotics containing a 7p-(a-etherified oxyimino)-acylamido group, the oxyimino group having the syn configuration. This class of antibiotic compounds is characterised by high antibacterial activity against a range of gram-positive and gram-negative organisms coupled with particularly high stability to fi-lactamases produced by various gram-negative organisms.

20 The discovery of this class of compounds has stimulated further research in the same area in attempts to find compounds which have improved properties, for example against particular classes of organisms, especially gram-negative organisms.

For example, in our British Patent Specification No. 1,496,757, we describe cephalosporin antibiotics containing a 7|>acylamido group of formula 25 R. C. CO. Kit—

N ? (A)

\). (CH2)m C (CH2>nC001l R0

30 (wherein R is a thienyl or furyl group; RA and RB may vary widely and may, for example, be Cv4 alkyl groups or together with the carbon atom to which they are attached form a C3.7 cycloalkylidene group, and m and n are each 0 or 1 such that the sum of m and n is 0 or 1), the compounds being syn isomers or mixtures of syn and anti isomers containing at least 90% of the syn isomer. The 3-position of the cephalosporin molecule may be unsubstituted or may contain one of a wide variety of possible substituents. These compounds have 35 been found to have particuarly good activity against gram-negative organisms.

Other compounds of similar structure have been developed from these compounds in further attempts to find antibiotics having improved broad spectrum antibiotic activity and or high activity against gram-negative organisms. Such developments have involved variations not only in the 7p-acylamido group of formula (A) but also the introduction of particular groups in the 3-position of the cephalosporin molecule. 40 Thus, South African Patent Specification 78 1870 describes cephalosporin compounds wherein the

7p-acylamido side-chain is inter alia a 2-(2-aminothiazol-4-yl)-2-(optionally substituted alkoxyimino)acetami-do group. In these compounds, the substituent in the 3-position may be selected from a wide variety of organic radicals including inter alia a group of formula -CH2RX where Rx may be a residue of a nucleophile, the specification containing numerous examples of such nucleophiles, including nitrogen nucleophiles. The 45 specification also contains, among numerous other examples, references to compounds in which the above-mentioned optionally substituted alkoxyimino group is a carboxyalkoxyimino or carboxycycloalkoxy-imino group. South African Patent Specification 78 2168 discloses in broad terms sulphoxide compounds corresponding to the sulphides described in the last-mentioned Specification.

Belgian Patent Specification No. 836,813 describes cephalosporin compounds wherein the group R in 50 formula (A) may be replaced by, for example, 2-aminothiazol-4-yl and the oxyimino group is a hydroxyimino or blocked hydroxyimino group. In such compounds, the 3-position of the cephalosporin molecule is substituted by a methyl group which may itself be optionally substituted by any of a large number of residues of nucleophilic compounds therein described. Examples of such residues include pyridinium, substituted pyridinium and quinolinium groups. In this specification no antibiotic activity is ascribed to such 55 compounds which are only mentioned as intermediates for the preparation of antibiotics therein described. South African Patent Specification 77 2030 discloses compounds wherein the 3-position substituent is as described in the above-mentioned Belgian Specification, but wherein the oxyimino group of the group R is restricted to a methoxyimino group. These compounds are stated to possess antibiotic activity.

South African Patent Specification No. 78/1502 describes cephalosporin compounds wherein the group R 60 in formula A may be replaced by for example 2-amino-thiazol-4-yl, and the oxyimino grouping may be substituted by an aliphatic hydrocarbon group which can itself be substituted by inter alia a carboxy group. In these compounds, the substituent at the 3-position is confined to hydrogen, halogen, lower alkyl, hydroxy, lower alkoxy or acyloxy. South African Patent Specification 78/1630 describes inter alia compounds similar structure but wherein the substituent in the 3-position is limited to an acetoxymethyl group.

65 We have now discovered that by an appropriate selection of a small number of particular groups at the

5

10

15

20

25

30

35

40

45

50

55

60

65

2

GB 2 043 641 A

2

7(3-position in combination with a pyridazinium-methyl group at the 3-position, compounds having particularly good activity (described in more detail below) against a wide range of commonly encountered pathogenic organisms may be obtained.

The present invention provides cephalosporin antibiotics of the general formula:

(wherein Ra and Rb, which may be the same or different, each represents a Ci„4 alkyl group, preferably a straight chain alkyl group, i.e. a methyl, ethyl, n-propyl or n-butyl group and particularly a methyl or ethyl 15 group, or, together with the carbon atom to which they are attached, form a C3.7 cycloalkylidene group 15

preferably a C3.5 cycloalkylidene group and non-toxic salts and non-toxic metabolically labile esters thereof.

The compounds according to the invention are syn isomers. The syn isomeric form is defined by the configuration of the group

Ra

20 | 20

-O.C.COOH

I

Rb

25 with respect to the carboxamido group. In this specification the syn configuration is denoted structurally as 25

X1

S N

I C.CO.NH

30 f 30

O.C.COOH

It will be understood that since the compounds according to the invention are capable of geometric 35 isomerism, some admixture with the corresponding anf/'isomer may occur. 35

The invention also includes within its scope the solvates (especially the hydrates) of the compounds of formula (I). It also includes within its scope salts of esters of compounds of formula (I).

The compounds according to the present invention may exist in tautomeric forms (for example in respect ofthe2-aminiothiazolyl group) and it will be understood that such tautomeric forms, e.g. the 40 2-iminothiazolinyl form, are included within the scope of the invention. Moreover, the compounds of 40

formula (I) depicted above may also exist in alternative zwitterionic forms, for example wherein the 4-carboxyl group is protonated and the terminal carboxyl group in the 7-side chain is deprotonated. Such zwitterionic forms and mixtures thereof are included within the scope of the present invention.

It will also be appreciated that when Ra and Rb in formula (1) represent different C,.4 alkyl groups the carbon 45 atom to which they are attached will comprise a centre of asymmetry. Such compounds are diastereo- 45

isomeric and the present invention embraces individual diasteroisomers of these compounds as well as mixtures thereof.

The compounds according to the invention exhibit broad spectrum antibiotic acitivity. Against gram-negative organisms the activity is unusually high. This high activity extends to many p-lactamase-50 producing gram-negative strains. The compounds also possess high stability to p-lactamases produced by a 50 range of gram-positive and gram-negative organisms.

Compounds according to the invention have been found to exhibit unusually high activity against strains of Pseudomonas organisms, e.g. strains or Pseudomonas aeruginosa as well as high activity against various members of the Enterobacteriaceae (e.g. strains of Escherichia coti, Klebsiella pneumoniae. Salmonella 55 typhimurium, Enterobacter cloacae, Serratia marcescens. Providence species, Proteus mirabilis and 55

especially indole positive Proteus organisms such as 'Proteus vulgaris and Proteus morganii), and strains of Haemophilus influenzae.

The antibiotic properties of the compounds according to the invention compare very favourably with those of the aminoglycosides such as amikacin or gentamicin. In particular, this applies to their activity against 60 strains of various Pseudomonas organisms which are not susceptible to many existing commercially 60

available antibiotic compounds. Unlike the aminoglycosides, cephalosporin antibiotics normally exhibit low toxicity in man. The use of aminoglycosides in human therapy tends to be limited or complicated by the relatively high toxicity of these antibiotics. The cephalosporin antibiotics of the present invention thus possess potentially great advantages over the aminoglycosides.

65 Non-toxic salt derivatives which may be formed from the compounds of general formula (I) include 65

3

GB 2 043 641 A

3

inorganic base salts such as alkali metal salts (e.g. sodium and potassium salts) and alkaline earth metal salts (e.g. calcium salts); amino acid salts (e.g. lysine and arginine salts); organic base salts (e.g. procaine, phenethylbenzylamine, dibenzylethylenediamine, ethanolamine, diethanolamine and N-methyl-glucosamine salts). Other non-toxic salt derivatives include acid addition salts, e.g. formed with 5 hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, formic and trifluoroacetic acids. The salts may also be in the form of resinates formed with, for example, a polystyrene resin or cross-linked polystyrene divinylbenzene copolymer resin containing amino or quaternary amino groups or sulphonic acid groups, or with a resin contaning carboxyl groups, e.g. a polyacrylic acid resin. Soluble base salts (e.g. alkali metal salts such as the sodium salt) of compounds of formula (I) may be used in therapeutic applications because of the 10 rapid distribution of such salts in the body upon administration. Where, however, insoluble salts of compounds (I) are desired in a particular application, e.g. for use in depot preparations, such salts may be formed in conventional manner, for example with appropriate organic amines.

These and other salt derivatives such as the salts with toluene p-sulphonic and methanesulphonicacids may be employed as intermediates in the preparation and/or purification of the present compounds of 15 formula (I), for example in the processes described below.

Non-toxic metabolically labile ester derivatives which may be formed from the parent compound of formula (I) include acyloxyalkyl esters, e.g. lower alkanoyloxymethyl or-ethyl esters such as acetoxymethyl or-ethyl or pivaloyloxymethyl esters. In addition to the above ester derivatives, the present invention includes within its scope compounds of formula (I) in the form of other physiologically acceptable equivalents, i.e. 20 physiologically acceptable compounds which, like the metabolically labile esters, are converted in vivo into the parent antibiotic compound of formula (I).

Preferred compounds according to the invention include those compounds of formula (I) wherein Ra and Rb both represent methyl groups or together with the carbon atom to which they are attached form a cyclobutylidene group i.e. (6R, 7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetam'ido]-3-25 (pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate and (6R,7R)-7-[ (Z) -2-(2-aminothiazol-4-yl)-2-(1-

carboxycyclobut-1-oxyimino)-acetamido]-3-(pyridazinium-1-ylmethyl) ceph-3-em-4-carboxylate, and their non-toxic salts and non-toxic metabolically labile esters.

Other compounds according to the present invention include those for example wherein both of the groups Ra and Rb are ethyl groups, or wherein one of Ra and Rb is methyl and the other is ethyl. Further 30 examples are provided by those compounds in which Ra and Rb together with the carbon atom to which they are attached form a cyclopropylidene or a cyclopentylidine group.

The above described compounds of formula (I) may be used for treating a variety of diseases caused by pathogenic bacteria in human beings and animals, such as respiratory tract infections and urinary tract infections.

35 According to a further embodiment of the present invention we provide a process for the preparation of compounds of formula (I) as hereinbefore defined or non-toxic salts or non-toxic metabolically labile esters thereof which comprises (A) acylating a compound of the formula

H H

1 I

[wherein B is >S or >S^0 (a- or |3 -) and the dotted line bridging the 2-, 3- and 4-positions indicates that the 45 compound is a ceph-2-em or ceph-3-em compound], or an acid addition salt (formed with, for example, a mineral acid such as hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid or an organic acid such as methane-sulphonic or toluene-p-sulphonic acid) or an N-silyl derivative thereof, or a corresponding compound possessing a group of theformula -COOR1 at the 4-position where R1 is a hydrogen atom or a carboxyl blocking group e.g. the residue of an ester-forming aliphatic or araliphatic alcohol or an 50 ester-forming phenol, silanol orstannanol (the said alcohol, phenol, silanol or stannanol preferably contaning 1 to 20 carbon atoms) and having an associated anion A" such as a halide, e.g. chloride or bromide, ortrifluoroacetate ion, with an acid of formula

—C.C00H

N Ra (II1)

\ • 2 O.C.COOH

Rb

60

[wherein Ra and Rb are as hereinbefore defined; R2 represents a carboxyl blocking group (e.g. as described for R1) and R3 is an amino or protected amino group] or with an acylating agent corresponding thereto, or (B) reacting a compound of formula

5

10

15

20

25

30

35

40

45

50

55

60

4

GB 2 043 641 A

4

W_C.C0.NH j (IV)

_ '' Ra ) N\^~CH X

5 N. I 0 2

O.C.COOR coop/'

ib

(wherein Ra, Rb, R3, B and the dotted line are as herein before defined; R4 and R4a may independently 10 represent hydrogen or a carboxyl blocking group; and X is a replaceable residue of a nucleophile, e.g. an acetoxy or dichloroacetoxy group or a halogen atom such as chlorine, bromine or iodine) or a salt thereof, with pyridazine; whereafter, if necessary and/or desired in each instance, any of the following reactions, in any appropriate sequence, are carried out:-i) conversion of a A2-isomer into the desired A3- isomer,

15 ii) reduction of a compound wherein B is > S->0toform a compound wherein B is >S,

iii) conversion of a carboxyl group into a non-toxic salt or non-toxic metabolically labile ester function, and iv) removal of any carboxyl blocking and/or N-protecting groups.

In the above-described process (A), the starting material of formula (II) is preferably a ceph-3-em compound.

Acylating agents which may be employed in the preparation of compounds of formula (I) include acid 20 halides, particularly acid chlorides or bromides. Such acylating agents may be prepared by reacting an acid (III) or a salt thereof with a halogenating agent e.g. phosphorus pentachloride, thionyl chloride or oxalyl chloride.

Where an acid addition salt of the compound of formula (II) is used, this is generally treated with a base priorto reaction with the compound of formula (III) or an acylating agent corresponding thereto. 25 Acylations employing acid halides may be effected in aqueous and non-aqueous reaction media conveniently at temperatures of from —50 to 4-50°C preferably —20 to +30CC, if desired in the presence of an acid binding agent. Suitable reaction media include aqueous ketones such as aqueous acetone, esters such as ethyl acetate, halogenated hydrocarbons such as methylene chloride, amides such as dimethylacetamide, nitriles such as acetonitrile, or mixtures of two or more such solvents. Suitable acid binding agents include 30 tertiary amines (e.g. triethylamine or dimethylaniline), inorganic bases (e.g. calcium carbonate or sodium bicarbonate), and oxiranessuch as lower 1,2-alkylene oxides (e.g. ethylene oxide or propylene oxide) which bind hydrogen halide liberated in the acylation reaction.

Acids of formula (III) may themselves be used as acylating agents in the preparation of compounds of formula (I). Acylations employing acids (III) are desirably conducted in the presence of a condensing agent, 35 for example a carbodiimide such as ISI,IM'-dicyclo-hexylcarbodiimide or N-ethyl-N'-y-

dimethylaminopropylcarbodiimide; a carbonyl compound such as carbonyldi-imidazole; or an isoxazolium salt such as N-ethyl-5-phenylisoxazolium perchlorate.

Acylation may be effected with other amide-forming derivatives of acids of formula (III) such as, for example, an activated ester, a symmetrical anhydride or a mixed anhydride (e.g. formed with pivalic acid or 40 with a haloformate such as a lower alkylhaloformate).

Mixed anhydrides may also be formed with phosphorus acids (for example, phosphoric or phosphorous acids), sulphuric acid or aliphatic or aromatic sulphonic acids (for example toiuene-p-sulphonic acid).

An activated ester may conveniently be formed in situ using, for example, 1-hydroxybenzotriazole in the presence of a condensing agent as set out above. Alternatively, the activated ester may be preformed. 45 Acylation reactions involving the free acids of their above mentioned amide-forming derivatives are desirably effected in an anhydrous reaction medium e.g. methylene chloride, tetrahydrofuran, dimethyl-formamide or acetonitrile.

If desired, the above acylation reactions may be performed in the presence of a catalyst, e.g.4-dimethylaminopyridine.

50 The amino acids of formula (III) and acylating agents corresponding thereto may, if desired, be prepared and employed in the form of their acid addition salts. Thus, for example, acids chlorides may conveniently be employed as their hydrochloride salts and acid bromides as their hydrobromide salts.

In process (B) above, pyridazine may displace a wide variety of substituentsX from the cephalosporin of formula (IV). To some extent the facility of the displacement is related to the pKa of the acid HXfrom which 55 the substituent is derived. Thus, atoms or groups X derived from strong acids tend, in general, to be more easily displaced than atoms or groups derived from weaker acids.

The displacement of X by pyridazine may conveniently be effected by maintaining the reactants in solution or suspension. The reaction is advantageously effected using from 1 to 10 moles e.g. 1 to 5 moles of pyridazine in a suitable reaction medium. Alternatively pyridazine itself may be used as a solvent. 60 Nucleophilic displacement reactions may conveniently be carried out on those compounds of formula (IV) wherein the substitutent X is a halogen atom or an acyloxy group, for example as discussed below.

Acyloxy groups

Compounds of formula (IV) wherein X is an acetoxy group are convenient starting materials for use in the 65 nucleophilic displacement reaction with pyridazine. Alternative starting materials in this class include

5

10

15

20

25

30

35

40

45

50

55

60

65

5

5

10

15

20

25

30

35

40

45

50

55

60

65

5

GB 2 043 641 A

compounds of formula (IV) in which X is the residue of a substituted acetic acid e.g. chloroacetic acid, dichloroacetic acid and trifluoroacetic acid.

Displacement reactions on compounds of formula (IV) possessing X substituents of this class, particularly in the case where X is an acetoxy group, may be facilitated by the presence in the reaction medium of iodide 5 orthiocyanate ions.

The substituent X may also be derived from formic acid, a haloformic acid such as chloroformic acid, or a carbamicacid.

When using a compound of formula (IV) in which X represents an acetoxy or substituted acetoxy group, it is generally desirable that the group R4 in formula (IV) should be a hydrogen atom and that B should 10 represent>S. In this case, the reaction is advantageously effected in an aqueous medium.

Under aqueous conditions, the pH value of the reaction solution is advantageously maintained in the range 6-8, if necessary by the addition of a base. The base is conveniently an alkali metal or alkaline earth metal hydroxide or bicarbonate such as sodium hydroxide or sodium bicarbonate.

When using compounds of formula (IV) in which X is an acetoxy group, the reaction is conveniently 15 effected at a temperature of 0°Cto 120°C, preferably 70°C to 90°C.

The above described process employing compounds of formula (IV) in which X is the residue of a sutstituted acetic acid may be carried out as described in British Patent Specification No. 1,241,657.

Halogens

20 Compounds of formula (IV) in which X is a chlorine, bromine or iodine atom can also be conveniently used as starting materials in the nucleophilic displacement reaction with pyridazine. When using compounds of formula (IV) in this class B may represent > S->0 and R4 may represent a carboxyl blocking group. The reaction is conveniently effected in a non-aqueous medium which preferably comprises one or more organic solvents, advantageously of a polar nature such as ethers, e.g. dioxan or tetrahydrofuran, esters, e.g. ethyl 25 acetate, amides, e.g. formamide or N,N-dimethy!formamide or ketones e.g. acetone. Other suitable organic solvents are described in more detail in British Patent Specification No. 1,326,531.

In the case of reactions carried out on compounds of formula (IV) in which R4 and R4a are carboxyl blocking groups the products will be formed as the corresponding halide salts which may, if desired, be subjected to one or more ion exchange reactions to obtain salts having the desired anion.

30 When using compounds of formula (IV) in which X is a halogen atom as described above, the reaction is conveniently effected at a temperature of 0°to +60°, preferably 4-15° to +30°C.

The reaction of the compound of formula (IV) with pyridazine may be carried out in the presence of an acid scavenging agent.

Pyridazine may, if desired, be added as an acid addition salt, e.g. the hydrochloride, where a base is 35 present in the reaction medium to liberate free pyridazine. The base should of course be less nucleophilic than pyridazine to avoid competitive reaction with the compound of formula (IV).

The reaction product may be separated from the reaction mixture, which may contain, for example, unreacted nucleophile and other substances, by a variety of processes including recrystallisation, ionophoresis, column chromatography and use of ion-exchangers (for example by chromatography on 40 ion-exchange resins) or macroreticular resins.

A A2-cephalosporin ester derivative obtained in accordance with the process of the invention may be converted into the corresponding A3 -derivative by, for example, treatment of the A2-ester with a base such as pyridine or triethylamine.

Aceph-2-em reaction product may also be oxidised to yield the corresponding ceph-3-em 1-oxide, for 45 example by reaction with a peracid e.g. peracetic or m-chloroperbenzoic acid, the resulting sulphoxide may, if desired, subsequently be reduced as described hereinafter to yield the corresponding cept-3-em sulphide.

Where a compound is obtained in which B is >S->0 this may be converted into the corresponding sulphide by, for example, reduction of the corresponding acyloxy-sulphonium salt prepared in situ by reaction with e.g. acetyl chloride in the case of an acetoxy-sulphonium salt, reduction being effeted by, for example, 50 sodium dithionite or by iodide ion as in a solution of potassium iodide in a water miscible solvent e.g. acetic acid, acetone, tetrahydrofuran, dioxan, dimethylformamide or dimethylacetamide. The reaction may be effected at a temperature between -20° to +50°C.

Metabolically labile ester derivatives of the compounds of formula (I) may be prepared by reacting a compound of formula (I) or a salt or protected derivative thereof with the appropriate esterifying agent such 55 as an acyloxymethyl halide (e.g. iodide), conveniently in an inert organic solvent such as diemthylformamide or acetone, followed, where necessary, by removal of any protecting groups.

Base salts of the compounds of formula (I) may be formed by reacting an acid of formula (I) with an appropriate base. Thus, for example, sodium or potassium salts may be prepared using the respective 3-ethylhexanoate or hydrogen carbonate salts. Acid addition salts may be prepared by reacting a compound 60 of formula (I) or a metabolically labile ester derivative thereof with the appropriate acid.

Where a compound of formula (I) is obtained as a mixture of isomers, the syn isomer may be obtained by, for example, conventional methods such as crystallisation or chromatography.

For use as starting materials for the preparation of the compounds of formula (I) according to the invention, compounds of general formula (III) and acid halides and anhydrides corresponding thereto in their 65 syn isomeric form, or in the form of mixtures of the syn isomers and the corresponding anti isomers

6

GB 2 043 641 A

6

containing at least 90% of the syn isomer, are preferably used.

Acids of formula (III) (provided that Ra and Rb together with the carbon atom to which they are attached do not form a cyclopropylidene group) may be prepared by etherification of a compound of formula

(v)

10 ... . 10

(wherein R3 is as hereinbefore defined and Rs represents a carboxyl blocking group) by reaction with a compound of general formula

Ra

15 | ( 15

TfCOOR!. (VII

Rb

20 (wherein Ra, Rb, and R2 are as hereinbefore defined and T is halogen such as chloro, bromo, or iodo; 20

sulphate; orsulphonate such as tosylate) followed by removal of the carboxyl block group R5.

Acids of general formula (III) may also be prepared by reaction of a compound of formula

R3

25 X 25

A <vn)

\ — l—co.coor5

(wherein R3 and R5 are as hereinbefore defined) with a compound of formula 30 30

Ra

!

H2N.O.C.COOR2 (Vlll)

I

35 Rb 35

wherein Ra, Rb and R2 are as defined above), followed by removal of the carboxyl blocking group R5.

The last mentioned reaction is particularly applicable to the preparation of acids of formula (III) wherein Ra and Rb together with the carbon atom to which they are attached form a cyclopropylidene group.

40 These methods of preparing the acids are described in more detail in Belgian Patent Specification No. 40

876538.

The acids of formula (III) may be converted to the corresponding acid halides and anhydrides and acid addition salts by conventional methods.

Where X is a halogen (i.e. chlorine, bromine or iodine) atom in formula (IV), ceph-3-em starting 45 compounds may be prepared in conventional manner, e.g. by halogenation of a 7p-protected amino-3- 45

methylceph-3-em-4-carboxylic acid ester 7|3-protected amino-3-methylceph-3-em-4-carboxylic acid ester 1f>-oxide, removal of the7[3-protecting group, acylation of the resulting 7|3-amino compound to form the desired 7|3-acylamido group, e.g. in an analogous manner to process (A) above, followed by reduction of the ip-oxide group later in the sequence. This is described in British Patent No. 1,326,531. The corresponding 50 ceph-2-em compounds may be prepared by the method of Dutch published Patent Application No. 6,902,013 50 for example by reaction of a 3-methylceph-2-em compound with N-bromosuccinimide to yield the corresponding 3-bromomethylceph-2-em compound.

Where X in formula (IV) is an acetoxy group, such starting materials may be prepared for example by acylation of 7-aminocephalosporanic acid, e.g. in an analogous mannerto process (A) above. Compounds of 55 formula (IV) in which X represents other acyloxy groups can be prepared by acylation of the corresponding 55 3-hydroxymethyl compounds which may be prepared for example by hydrolysis of the appropriate 3-acetoxymethyl compounds e.g. as described inter alia in British Patent Specifications 1,474,519 and 1,531,212.

Compounds of formula (II) may likewise be prepared in conventional manner, e.g. by nucleophilic 60 displacement of a corresponding 3-acyloxymethyl or 3-halomethyl compound with pyridazine. 60

A further method for the preparation of starting materials of formula (II) comprises deprotecting the corresponding protected 7[3-amino compound in conventional manner, e.g. using PCls.

It is to be noted that compounds of formula (II) are novel and constitute a further aspect of the present invention.

65 It should be appreciated that in some of the above transformations it may be necessary to protect any 65

7

GB 2 043 641 A

7

sensitive groups in the molecule of the compound in question to avoid undesirable side-reactions. For example, during any of the reaction sequences referred to above it may be necessary to protect the NH2 group of theaminothiazolyl moiety, for example by tritylation, acylation (e.g. chloroacetylation), protonation or other conventional method. The protecting group may thereafter be removed in any convenient way 5 which does not cause breakdown of the desired compound, e.g. in the case of a trityl group by using an optionally halogenated carboxylic acid such as acetic acid, formic acid, chloroacetic acid or trifluoroacetic acid or using a mineral acid, e.g. hydrochloric acid or mixtures of such acids, conveniently in the presence of a protic solvent such as water or, in the case of a chloroacetyl group, by treatment with thiourea.

Carboxyl blocking groups used in the prepration of the compounds of formula (I) or in the preparation of 10 necessary starting materials are desirably groups which may readily be split off at a suitable stage in the reaction sequence, conveniently at the last stage. It may, however, be convenient in some instances to employ biologically acceptable, metabolically labile carboxyl blocking groups such as acyloxy-methyl or -ethyl groups (e.g. acetoxy-methyl or -ethyl and pivaloyloxymethyl groups) and retain these in the final product to give a biologically acceptable ester derivative of the compound of formula (I).

15 Suitable carboxyl blocking groups are well known in the art, a list of representative blocked carboxyl groups being included in British Patent No. 1,399,086. Preferred blocked carboxyl groups include aryl lower alkoxycarbonyl groups such asp-methoxybenzyloxycarbonyl,p-nitrobenzyloxycarbonyl and dipheny-Imethoxycarbonyl; f-butoxycarbonyl; and lower haloalkoxycarbonyl groups such as 2,2,2-trichloroethoxycarbonyl. Carboxyl blocking group(s) may subsequently be removed by any of the 20 appropriate methods disclosed in the literature; thus, for example, acid or base catalysed hydrolysis is applicable in many cases, as are enzymically-catalysed hydrolyses.

The following Examples illustrate the invention. All temperatures are in °C. "Ether" refers to diethyl ether. Proton magnetic resonance spectra were determined on the products at 100 MHz. The integrals were in agreement with the assignments; the signs of the coupling constants, J, in Hz, were not determined. The 25 following abbreviations are used:

s = singlet, d = doublet, m = multiplet and ABq = AB-quartet.

Preparation 1

Dipheny/methyi (1S,6R,7Rj-7-Formamido-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate, 1-oxide, 30 Bromide Salt

A solution of diphenylmethyl (1S,6R,7R)-3-bromomethyl-7-formamidoceph-3-em-4-carboxylate, 1-oxide (4.2 g) in N, N-dimethylformamide (12 ml) was treated with pyridazine (1.34 g) and stirred for 16 hours at 22°.

The solution was treated with ether (50 ml) and tetrahydrofuran (50 ml) to give a gum which was stirred with fresh tetrahydrofuran. The resulting solid was washed with tetrahydrofuran and ether to give the title 35 compound (4.4 g), vmax (Nujol) 3700 to 2700 (NH), 1796 ((3-lactam), 1729 (C02R) and 1686cm-1 (CONH) and r (DMSO-d6) 0.08 (d, J 5Hz, pyridazinium 6-H),0.43 (d, J 5Hz, pyridazinium 3-H), 1.1 to 1.4 (m, pyridazinium 4-H and 5-H), and 3.96 and 4.18 (ABq, J 15Hz, 3-CH2).

Preparation 2

40 Diphenylmethyl (1S,6R,7R)-7-Amino-3-(pyridazinium- 1-ylmethy/Jceph-3-em-4-carboxylater 1-oxide, Hydrochloride!Bromide Salt

The product from Preparation 1 (0.583 g) was stirred with methanol (5 ml) at 0° to give a gummy solid.

The mixture was treated with phosphoryl chloride (0.46 g). A solution was obtained after 15 minutes and stirring was continued below 10° for 2 hours.

45 Dropwise addition of the above solution to ether (600 ml) gave a gummy solid which was stirred with ethyl acetate (40 ml) for 30 minutes. The product was collected and washed with ether to give the title compound (0.43 g) as a solid, Xmax(EtOH) 274 nm (E^ 123) and vmax(Nujol) 3420 (H20), 3700 to 2100 NH®, 1802 (P-Iactam), 1729 (C02R) and 1028 cm"-1 (S->0).

50 Example 1

a) Diphenylmethyl (1S,6R, 7R)-7-[(Z)-2-(2-t-Butoxy-carbonylprop-2-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetamido]-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate, 1-oxide, Bromide Salt.

A solution of diphenylmethyl (1 S,6R,7R)-3-bromomethyl-7-[(z)-2-(2-t-butoxycarbonylprop-2-oxyimino)-2-(2-tritylaminothiazol-4-yl)-acetamido]ceph-3-em-4-carboxylate, 1-oxide (1.24 g) in dry tetrahydrofuran (6 ml) 55 was treated with pyridazine (0.088 ml) and the solution was stirred at 24° for 2 hours then left to stand at ca 20° for 88 hours.

The reaction mixture was added slowly to stirred ether (150 ml) and the lilac precipitate was filtered off and washed with ether and dried in vacuo to give the title ester (1.10 g) as a solid, m.p. 147 to 154° (with decomposition), Xinf (EtOH) 240 nm (E]^231, e26,400), 265 nm (E^ 90, e10,400) and 305 nm (E]^ 67, e7,650). 60 b) Diphenylmethyl (6R, 7R)-7-f(Z)-2-(t-Butoxycarbony/prop-2-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetamido]-3-(pyridazinium- 1-ylmethyljceph-3-em-4-carboxylate, Iodide and Bromide Salts

Acooled (-10°) and stirred mixture of the product from (a) (1.00 g) and potassium iodide (0.600 g) in acetone (5 ml) was treated with acetyl chloride (0.13 ml) and the mixture was stirred at Oto +2° for 1 hour.

The product was added slowly to a stirred solution of sodium metabisulphite (0.8 g) in water (80 ml) and 65 the resultant precipitate was filtered off, washed with water and dried in vacuo over phosphorous pentoxide

5

10

15

20

25

30

35

40

45

50

55

60

65

8 GB 2 043 641 A

8

to give a solid (0.989 g).

A similar reduction sequence using potassium iodide (0.600 g), acetone (5 ml) and acetyl chloride was repeated on the above product and the resultant precipitate was filtered off, washed with water and dried in vacuo over phosphorus pentoxide to give a solid (1.0 g).

5 The solid was partitioned between ethyl acetate (containing dichloromethane) and aqueous sodium 5

metabisulphite solution and the organic phase was separated and washed with water and dried and evaporated to give a foam which, on trituration with ether, gave the title compound (0.87 g) as a solid;

[a]D—20° lc0.25, CHCI3),Xinfi. (EtOH) 238 nm (E]%, 265, e29,400), 264 nm (E]%, 160, e17,700) and 299 nm (E]%,

81, e 9,000).

10 c) (6R,7R}-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamido]-3-(pyridazinium-1- 10 »

ylmethyl)ceph-3-em-4-carboxylate

The product of stage (b) (0.77 g) was dissolved in anisole (0.8 ml) and trifluoroacetic acid (3.2 ml) was added. The mixture was swirled at 22° for 3 minutes and then evaporated in vacuo to give a liquid. Trituration of this liquid with ether gave a precipitate which was filtered off and washed with ether and dried in vacuo to 15 give a solid (0.54 g). 15

This solid was wetted with anisole (0.12 ml) and then treated with trifluoroacetic acid (15 ml). The solution (containing a slight suspension) was swirled at 22° for 15 minutes. The mixture was filtered and the filtrate was evaporated to an oil, which, on trituration with ether: ethyl acetate (2:1) afforded a precipitate.

The precipitate was filtered off and washed with ether and dried in vacuo to give the title compound 20 associated with 1.5 moles of trifluoroacetic acid (0.468g), Xmax (pH 6 buffer) 237 nm (E}^ 295, el 9,800) and 20

Xinf, 295 nm (E^ 117, £8,600), vmax (Nujol) 3700 to 2200 (NH, NH2 and OH), 1786 (p-lactam), 1720 (sh) (free acid) and 1670 cm-1 (COJ).

Example 2

25 (6R, 7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamidoJ-3-(pyridazinium-1- 25

ylmethyl)ceph-3-em-4-carboxyiate, sodium salt.

(6R,7R)-3-acetoxymethyl-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamido]ceph-3-em-4-carboxylic acid (0.264 g), sodium hydrogen carbonate (0.105 g), sodium iodide (0.9 g), pyridazine (0.073 ml) and water (0.2 ml) were heated together at 76° for 2 1/4 hours.

30 The solution was allowed to cool and the resulting solid was dissolved by warming with water (0.6 ml). 30

The solution was added dropwise to stirred acetone (150 ml) and the precipitate was filtered off and washed with acetone and ether and was dried in vacuo to give the title compound (0.284 g) as a solid.

t(D20) 0.24 (m, pyridazinium 6-H), 0.60 (m, pyridazinium 3-H), 1.4-1.7 (broad m, pyridazinium 4-and 5-H) 3.11 (s, thiazole 5-H), 4.1 - 4.6 (obscured ABq, 3- CH2), 4.21 (d, J 5HZ, 7-H) 4.79 (d, J 5Hz, 6-H), 6.27 and 6.55 (ABq J

35 18Hz, 2 - H2) 8.55 (s, CMe2). 35

Example 3

(6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(1-carboxycyclobut-1-oxyimino)acetamido]-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate, sodium salt 40 (6R,7R)-3-acetoxymethyl-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(1-carboxycyclobut-1-oxyimino)acetamido]ceph- 40 3-em-4-carboxylic acid (0.54 g), sodium hydrogen carbonate (0.21 g) sodium iodide (1.8 g), pyridazine (0.21 ml) and water (0.35 ml) were heated together at 80° for 1.25 hours. The solution was allowed to cool and the resulting solid was dissolved by warming with water (ca. 0.5 ml). The solution obtained was added slowly to stirred acetone (100 ml) and the precipitate was filtered off, washed with acetone and dried in vacuo to give a 45 solid (0.618 g). 45

This solid was purified on a column ofXAD2 resin (100g)eluted in 66 ml fractions. Elution was with water (fractions 1 to 11) then watenethanol (3:1) (fractions 12 to 18). Fractions 12 to 17 were combined and evaporated to ca. 250 ml and freeze-dried to a foam which, on trituration with ether gave the title compound (0.229 g) as a solid, [a]D + 19° (c 0.64, H20), Xmax (pH6 buffer) 242 nm (E}%, 302) with an inflection at 290 nm 50 (E^ 154). 50

Example 4

Diphenylmethyl (1S,6R,7R)-7-[(Z)-2-(2-t-Butoxycarbonylprop-2-oxyimino)-2-(2-tritylaminothiazol-4-yl)-acetamido]-3-(pyridazinium- 1-ylmethyl)ceph-3-em-4-carboxylate, 1-oxide, Bromide Salt 55 Phosphorus pentachloride (0.11 g) in dry dichloromethane (10 ml) at 0° was treated with (Z)-2-(2-t-butoxy- 55 carbonylprop-2-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetic acid (0.295 g) and the solution was stirred for 35 minutes at 0°. Triethylamine (0.16 ml) was added and stirring was continued for 5 minutes at 0°.

The resulting solution was added, dropwise, over 5 minutes to a vigorously stirred suspension of the product of Prep. 2 (0.301 g) in dichloromethane (15 ml) at 0°. The suspension was stirred with cooling for 15 60 minutes and without cooling for 1 hour. The mixture was left at 0° for 15 hours then poured into ethyl acetate 60 (100 ml) and water (100 ml). The organic phase was washed with water then dried and evaporated in vacuo to a foam which, on stirring with ether gave the title compound (0.13 g) as an amorphous solid. The ether liquors were evaporated to give further product (0.23 g).

The first crop of material had Xinf(EtOH) at 240 nm (E^ 253), 265 nm (E}%, 181) and 305 nm (E^76) and 65 vmax(CHBr3) 3500 to 3000 (NH), 1802 (|3-lactam); 1725 (esters), and 1680 and 1520 cm"1 (CONH). 65

9

GB 2 043 641 A

9

The title compound may be converted into (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxy-imino)acetamido]-3-pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate, by the methods described in Examples 1(b) and 1(c).

5 Pharmaceutical formulations

The antibiotic compounds of the invention may be formulated for administration in any convenient way, by analogy with other antibiotics and the invention therefore includes within its scope pharmaceutical compositions comprising an antibiotic compound in accordance with the invention adapted for use in human or veterinary medicine. Such compositions may be presented for use in conventional manner with 10 the aid of any necessary pharmaceutical carriers or excipients.

The antibiotic compounds according to the invention may be formulated for injection and may be presented in unit dose form in ampoules, or in multi-dose containers if necessary with an added , preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing 15 agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water before use.

If desired, such powder formulations may contain an appropriate non-toxic base in order to improve the water-solubility of the active ingredient and/or to ensure that when the powder is constituted with water, the pH of the resulting aqueous formulation is physiologically acceptable. Alternatively the base may be present 2Q in the water with which the powder is constituted. The base may be for example an inorganic base such as sodium carbonate, sodium bicarbonate or sodium acetate or an organic base such as lysine or lysine acetate.

The antibiotic compounds may also be formulated as suppositories e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For medication of the eyes or ears, the preparations may be formulated as individual capsules, in liquid or 25 semi-solid form, or as drops.

Compositions for veterinary medicine may also, for example, be formulated as intramammary preparations in either long acting or quick-release bases.

The compositions may contain from 0.1% upwards, e.g. 0.1-99% of the active material, depending on the method of administration. When the compositions comprise dosage units, each unit will preferably contain 30 50-1500 mg of the active ingredient. The dosage as employed for adult human treatment preferably ranges from 250 to 6000 mg per day, depending on the route and frequency of administration. For example, in adult human treatment 1000 to 3000 mg per day administered intravenously or intramuscularly should normally suffice. In treating Pseudomonas infections higher daily doses may be required.

The antibiotic compounds according to the invention may be administered in combination with other 35 therapeutic agents such as antibiotics, for example penicillins or ether cephalosporins.

The following formulations illustrate how the compounds according to the invention may be made up into pharmaceutical formulations.

Formulation - For Injection 40 Fill sterile (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino) acetamido]-3-(pyrid-

azinium-1-ylmethyl)ceph-3-em-4-carboxyIate monosodium salt into glass vials, such that each vial contains an amount equivalent to 500mg of the antibiotic acid. Carry out the filling aseptically under a blanket of sterile nitrogen. Close the vials using rubber discs, or plugs, held in position by aluminium overseals,

thereby preventing gaseous exchange or ingress of micro-organisms. Constitute the product by dissolving 45 in Water for Injections or other suitable sterile vehicle shortly before administration.

(6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(1-carboxycyclobut-1-oxyimino) acetamido]-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate may also be formulated for injection in the manner described above.

*

Claims (7)

CLAIMS 50

1. Cephalosporin antibiotics of general formula

60 (wherein Ra and Rb, which may be the same or different, each represents a Ct_4 alkyl group, or together with the carbon atom to which they are attached form a C3_7 cycloalkylidene group) and non-toxic salts and non-toxic metabolically labile esters thereof.

2. Compounds of formula (I) as claimed in claim 1 wherein Ra and Rb each represent methyl or ethyl groups.

65

3. Compounds of formula (I) as claimed in claim 1 wherein Ra and Rb together with the carbon atom to

5

10

15

20

25

30

35

40

45

50

55

60

65

10

GB 2 043 641 A

10

which they are attached form a C3_5 cycloalkylidene group.

4. (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamido]-3-(pyridazinium-1-ylmethyl)ceph-3-em-4-carboxylate and its non-toxic salts.

5. (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(1-carboxycyclobut-1-oxyimino)acetamido]-3-(pyridazinium-1-

5 ylmethyl)ceph-3-em-4-carboxylate and its non-toxic salts. 5

6. A process for the preparation of a compound of formula (I) as defined in claim 1 or a non-toxic salt or non-toxic metabolically labile ester thereof which comprises (A) acylating a compound of the formula

H H

i i

15 [wherein B is>S or >S^0 (a- or (3-) and the dotted line bridging the 2-, 3- and 4-positions indicates that the 15 compound is a ceph-2-em orceph-3-em compound], or an acid addition salt or an N-silyl derivative thereof, or a corresponding compound possessing a group of formula -COOR1 atthe4-position (where R1 is a hydrogen atom of carboxyl blocking group) and having an associated anion A", with an acid of formula

20 f3 20

— c..cooh

H R3 d")

\ ' 2 o.c.coor

25 25

[wherein Ra and Rb are as defined in claim 1; R2 represents a carboxyl blocking group; and R3 is an amino or protected amino group] or with an acylating agent corresponding thereto, or (B) reacting a compound of formula

30 r3 30

An 1 !<

c.co.nh ! (jv)

35 "o.c.coor"3 coor4 35

Ib

(wherein Ra, Rb, R3, B and the dotted line are as defined above;

R4 and R4a may independently represent hydrogen or a carboxyl blocking group; and X is a replaceable 40 residue of a nucleophile) or salt thereof, with pyridazine; whereafter, if necessary, and/or desired in each 40

instance, any of the following reactions in any appropriate sequence, are carried out:-

i) conversion of a A2-isomer into the desired A3-isomer,

ii) reduction of a compound where B is >S—>0 to form a compound wherein B is >S,

iii) conversion of a carboxyl group into a non-toxic salt or non-toxic metabolically labile ester function.

45 iv) removal of any carboxyl blocking and/or N-protecting groups. 45

7. A pharmaceutical composition for use in human or veterinary medicine comprising an antibiotic compound as claimed in any of claims 1 to 5 in association with a pharmaceutical carrier or excipient.

Printed for Her Majesty's Stationery Office, by Croydon Printing Company Limited, Croydon Surrey, 1980. Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.